Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19 and Other Community-Acquired Pneumonia.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05254990|
Recruitment Status : Recruiting
First Posted : February 24, 2022
Last Update Posted : February 27, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19.
- To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality.
- To evaluate the safety of oral reparixin versus placebo in the specific clinical setting.
|Condition or disease||Intervention/treatment||Phase|
|Infectious Pneumonia Severe COVID-19||Drug: Reparixin Other: Placebo||Phase 3|
Multinational, multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase III trial.
It will enrol 526 male and female patients >18 years, hospitalised for CAP (including COVID-19), assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days. Randomisation will be stratified according to disease severity and site.
All the patients will receive the standard of care based on their clinical need, including COVID-19 and CAP medications, as per local standard therapy at the trial site and in line with international guidelines.
The primary outcome will be evaluated at day 28, secondary will be evaluated from day 3 to day 180.
An independent external data monitoring committee (DMC) will oversee the study and evaluate unblinded interim data for efficacy, futility, and safety.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||526 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||male and female patients >18 years, hospitalised for COVID-19, will be assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomised, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)|
|Actual Study Start Date :||April 6, 2022|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||March 2024|
Experimental: Reparixin + standard of care
Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days.
The three daily doses will be administered maintaining an interval between doses of about 8 hours.
Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
Other Name: Repertaxin L-lysine salt
Placebo Comparator: Placebo + standard of care
Placebo tablets are identical in appearance to the active formulation. Placebo will be administered with the same treatment schedule.
Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.
Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion.
Other Name: Matched placebo
- Proportion of patients dead or requiring Invasive Mechanical Ventilation (IMV) or Extracorporeal Membrane Oxygenation (ECMO) by day 28 [NIAID-OS 7]. [ Time Frame: Day 28 ]NIAID-OS = National Institute of Allergy and Infectious Disease - Ordinal Scale
- All-cause mortality at day 180 [ Time Frame: Day 180 ]
- Proportion of patients alive and discharged at day 28 [ Time Frame: Day 28 ]
- Ventilatory-free days (VFD) at day 28 [ Time Frame: Day 28 ]Number of days from Day 0 to Day 28 when the patient will alive and free of invasive ventilation. In case of multiple periods of IMV during the first 28 days, the total duration of ventilation considered all periods of ventilation during the index admission. Patients who will die within 28 days or will be still on invasive ventilation after 28 days will score zero VFDs18
- Occurrence of IMV (or ECMO) by day 28 [ Time Frame: Day 28 ]
- Length of primary hospital stay [ Time Frame: Throughout the trial ]
- Clinical failure by day 3 and day 7 [ Time Frame: day 3 and day 7 ]Clinical failure will be defined as the occurrence of IMV/ECMO or vasopressor, or death
- 28-day ICU-free days [ Time Frame: Day 28 ]
- Days free of IMV/ECMO (number of days with NIAID-OS 1-6) at day 28 [ Time Frame: Day 28 ]
- Duration of antibiotic therapy (days) at day 28 [ Time Frame: Day 28 ]
- Hospital free days [ Time Frame: Day 28 ]
- Proportion of patients recovered [ Time Frame: days 3, 7±1, 14±2, 21±2, 28 ±2 or at hospital discharge ]downward shift from screening of ≤2 points on the NIAID-OS or live discharge from hospital)
- Proportion of patients worsening [ Time Frame: days 3, 7±1, 14±2, 21±2, 28 ±2 or at hospital discharge ]upward shift from screening of at least >1 point of the NIAID-OS)
- PO2/FiO2 [ Time Frame: days 3, 7±1, 14±2, 21±2, 28 ±2 or at hospital discharge ]
- All-cause mortality [ Time Frame: Days 28 and 90 ]
- Hospital re-admission by day 90 and 180 [ Time Frame: Days 90 and 180 ]
- Time to discharge or to a NEWS of ≤ 2 (for 24 hours), whichever occurs first [ Time Frame: Day 28 ]
- Change in inflammatory markers (LDH, CRP, ferritin; D-dimer, PCT) and cytokines [ Time Frame: Days 3, 7±1, 14±2, 21±2, 28±2 or at hospital discharge] ]
- Change in quality of life using EuroQol-5-dimensions-5 levels (EQ-5D-5L) questionnaire [ Time Frame: 90±7 and 180±14 days ]The EQ-5D-5L asks patients to indicate whether they have no, slight, moderate, severe, extreme problems on each of five dimensions of health: mobility; self-care; usual activities; pain/discomfort; anxiety/depression.
- Duration of IMV and/or ECMO at 90 and 180 days [ Time Frame: Days 90 and 180 ]
- ICU admission at 90 and 180 days [ Time Frame: Days 90 and 180 ]
- ICU length of stay at 90 and 180 days [ Time Frame: Days 90 and 180 ]
- Hospital length of stay at 90 and 180 days [ Time Frame: Days 90 and 180 ]
- Occurrence of infections at 90 and 180 days [ Time Frame: Days 90 and 180 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Informed consent signed
- Male and female ≥18 years old;
Patients hospitalized for clinically suspected CAP, defined as the occurrence of (within 48h from hospital admission):
- at least 1 of the following signs/symptoms: dyspnea, cough, purulent sputum, crackles (rales) and/or rhonchi
- body temperature > 38°C or <36°C (before or during admission) or leucocytosis (> local ULN)
- new/increased pulmonary infiltrate(s) by chest imaging
- Need for non-invasive supplemental oxygen (NIAID-OS 5-6; Appendix 14.4.1);
- SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300;
Females of child-bearing potential and with an active sexual life must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:
- Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last IMP dose
- A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last IMP dose
- A male sexual partner who agrees to use a male condom with spermicide
- A sterile sexual partner
Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, with child-bearing potential, pregnancy test result must be negative before first drug intake.
- Treatment with IMV or ECMO (NIAID-OS 7);
- Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score B or C);
- Renal dysfunction: estimated glomerular filtration rate (eGFR, MDRD) <50 mL/min/1.73 m2, or need for haemodialysis or hemofiltration;
- Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anaemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
- Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period (see section 5.5.2);
- Anticipated discharge from the hospital or transfer to another hospital within 72 hours of screening
- intolerance or hypersensitivity to ibuprofen to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib (hypersensitivity to sulphanilamide antibiotics alone, e.g. sulfamethoxazole does not qualify for exclusion)
- lactase deficiency, galactosemia or glucose-galactose malabsorption
- gastrointestinal bleeding or perforation due to previous NSAIDs therapy or recurrent peptic ulcer/haemorrhage
- allergy to reparixin or any component of the IMP formulation
- Active bleeding or bleeding diathesis (excluding menses), prior intracranial haemorrhage
- Participation in other interventional clinical trials
- Clinical condition not compatible with oral administration of the study drug
- positive or missing pregnancy test before first drug intake or day 1;
- pregnant or lactating women;
- women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
- Current hospital stay >72h
- Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05254990
|Contact: Maria De Pizzol, BSc||02 firstname.lastname@example.org|
|Contact: Cecilia Conz, BSc||02 email@example.com|
|Study Director:||Enrico Minnella, MD||Dompé Farmaceutici|
|Responsible Party:||Dompé Farmaceutici S.p.A|
|Other Study ID Numbers:||
2021-006951-32 ( EudraCT Number )
|First Posted:||February 24, 2022 Key Record Dates|
|Last Update Posted:||February 27, 2023|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Infectious pneumonia acquired in the community (CAP)
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases